Tetranectin and apolipoprotein A-I in cerebrospinal fluid as potential biomarkers for Parkinson's disease

Acta Neurologica Scandinavica

Volumn 122, Issue 5, 2010, Pages 350-359

  Wang, E S ^a,b   Sun, Y ^a,b   Guo, J G ^c   Gao, X ^a   Hu, J W ^d   Zhou, L ^a   Hu, J ^a   Jiang, C C ^a  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^d Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

Author keywords

Biomarker; Cerebrospinal Fluid; Parkinson'S Disease; Proteomics

Indexed keywords

APOLIPOPROTEIN A1; ISOPROTEIN; MYOSIN PHOSPHATASE TARGET SUBUNIT 1; PROTEIN; TETRANECTIN; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE DURATION; DISEASE MARKER; DOWN REGULATION; FEMALE; HUMAN; MALE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PARKINSON DISEASE; PROTEIN ANALYSIS; TWO DIMENSIONAL GEL ELECTROPHORESIS; UPREGULATION; WESTERN BLOTTING;

AGED; APOLIPOPROTEIN A-I; BIOLOGICAL MARKERS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; HUMANS; LECTINS, C-TYPE; MALE; MASS SPECTROMETRY; MIDDLE AGED; PARKINSON DISEASE; PROBABILITY;

EID: 78649372310     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2009.01318.x     Document Type: Article

References (46)

1. Michell AW, Lewis SJ, Foltynie T, Barker RA. Biomarkers and Parkinson's disease. Brain 2004;127:1693-705.
2. Zhang J, Sokal I, Peskind ER et al. CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am J Clin Pathol 2008;129:526-9.
3. Jesse S, Steinacker P, Lehnert S, Gillardon F, Hengerer B, Otto M. Neurochemical approaches in the laboratory diagnosis of Parkinson and Parkinson dementia syndromes: a review. CNS Neurosci Ther 2009;15:157-82.
4. Davidsson P, Sjogren M. The use of proteomics in biomarker discovery in neurodegenerative diseases. Dis Markers 2005;21:81-92.
5. Hu Y, Malone JP, Fagan AM, Townsend RR, Holtzman DM. Comparative proteomic analysis of intra- and interindividual variation in human cerebrospinal fluid. Mol Cell Proteomics 2005;4:2000-9.
6. Alban A, David SO, Bjorkesten L et al. A novel experimental design for comparative two-dimensional gel analysis: two-dimensional difference gel electrophoresis incorporating a pooled internal standard. Proteomics 2003;3:36-44.
7. Tonge R, Shaw J, Middleton B et al. Validation and development of fluorescence two-dimensional differential gel electrophoresis proteomics technology. Proteomics 2001;1:377-96.
8. Richard E, Monteoliva L, Juarez S et al. Quantitative analysis of mitochondrial protein expression in methylmalonic acidemia by two-dimensional difference gel electrophoresis. J Proteome Res 2006;5:1602-10.
9. Jin T, Hu LS, Chang M, Wu J, Winblad B, Zhu J. Proteomic identification of potential protein markers in cerebrospinal fluid of GBS patients. Eur J Neurol 2007;14:563-8.
10. Lehmensiek V, Sussmuth SD, Tauscher G et al. Cerebrospinal fluid proteome profile in multiple sclerosis. Mult Scler 2007;13:840-9.
11. Swatton JE, Prabakaran S, Karp NA, Lilley KS, Bahn S. Protein profiling of human postmortem brain using 2-dimensional fluorescence difference gel electrophoresis (2-D DIGE). Mol Psychiatry 2004;9:128-43.
12. Brechlin P, Jahn O, Steinacker P et al. Cerebrospinal fluid-optimized two-dimensional difference gel electrophoresis (2-D DIGE) facilitates the differential diagnosis of Creutzfeldt-Jakob disease. Proteomics 2008;8:4357-66.
13. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999;56:33-9.
14. Abdi F, Quinn JF, Jankovic J et al. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis 2006;9:293-348.
15. Mckhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-44.
16. Lassmann H, Reindl M, Rauschka H et al. A new paraclinical CSF marker for hypoxia-like tissue damage in multiple sclerosis lesions. Brain 2003;126:1347-57.
17. Liu XD, Zeng BF, Xu JG, Zhu HB, Xia QC. Proteomic analysis of the cerebrospinal fluid of patients with lumbar disk herniation. Proteomics 2006;6:1019-28.
18. Davidsson P, Paulson L, Hesse C, Blennow K, Nilsson CL. Proteome studies of human cerebrospinal fluid and brain tissue using a preparative two-dimensional electrophoresis approach prior to mass spectrometry. Proteomics 2001;1:444-52.
19. Yin GN, Lee HW, Cho JY, Suk K. Neuronal pentraxin receptor in cerebrospinal fluid as a potential biomarker for neurodegenerative diseases. Brain Res 2009;1265:158-70.
20. Klunk WE. Blood and CSF biomarkers for AD revisited: what's new, what's good, and is this where we should be looking? Neurobiol Aging 2002;23:517-9. discussion 21-2.
21. Sunderland T, Linker G, Mirza N et al. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 2003;289:2094-103.
22. Pan S, Rush J, Peskind ER et al. Application of targeted quantitative proteomics analysis in human cerebrospinal fluid using a liquid chromatography matrix-assisted laser desorption/ionization time-of-flight tandem mass spectrometer (LC MALDI TOF/TOF) platform. J Proteome Res 2008;7:720-30.
23. Sinha A, Srivastava N, Singh S et al. Identification of differentially displayed proteins in cerebrospinal fluid of Parkinson's disease patients: a proteomic approach. Clin Chim Acta 2009;400:14-20.
24. Waragai M, Wei J, Fujita M et al. Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson's disease. Biochem Biophys Res Commun 2006;345:967-72.
25. Reiber H. Proteins in cerebrospinal fluid and blood: barriers, CSF flow rate and source-related dynamics. Restor Neurol Neurosci 2003;21:79-96.
26. Clemmensen I, Petersen LC, Kluft C. Purification and characterization of a novel, oligomeric, plasminogen kringle 4 binding protein from human plasma: tetranectin. Eur J Biochem 1986;156:327-33.
27. Obrist P, Spizzo G, Ensinger C et al. Aberrant tetranectin expression in human breast carcinomas as a predictor of survival. J Clin Pathol 2004;57:417-21.
28. Wewer UM, Iba K, Durkin ME et al. Tetranectin is a novel marker for myogenesis during embryonic development, muscle regeneration, and muscle cell differentiation in vitro. Dev Biol 1998;200:247-59.
29. Wewer UM, Ibaraki K, Schjorring P, Durkin ME, Young MF, Albrechtsen R. A potential role for tetranectin in mineralization during osteogenesis. J Cell Biol 1994;127:1767-75.
30. Hogdall CK, Soletormos G, Nielsen D, Norgaard-Pedersen B, Dombernowsky P, Clemmensen I. Prognostic value of serum tetranectin in patients with metastatic breast cancer. Acta Oncol 1993;32:631-6.
31. Hammack BN, Fung KY, Hunsucker SW et al. Proteomic analysis of multiple sclerosis cerebrospinal fluid. Mult Scler 2004;10:245-60.
32. Stoevring B, Jaliashvili I, Thougaard AV et al. Tetranectin in cerebrospinal fluid: biochemical characterisation and evidence of intrathecal synthesis or selective uptake into CSF. Clin Chim Acta 2005;359:65-71.
33. Xiao F, Chen D, Lu Y et al. Proteomic analysis of cerebrospinal fluid from patients with idiopathic temporal lobe epilepsy. Brain Res 2009;1255:180-9.
34. Dietzmann K, Von Bossanyi P, Krause D, Wittig H, Mawrin C, Kirches E. Expression of the plasminogen activator system and the inhibitors PAI-1 and PAI-2 in posttraumatic lesions of the CNS and brain injuries following dramatic circulatory arrests: an immunohistochemical study. Pathol Res Pract 2000;196:15-21.
35. Mcguire KA, Davidson WS, Jonas A. High yield overexpression and characterization of human recombinant proapolipoprotein A-I. J Lipid Res 1996;37:1519-28.
36. Suehiro T, Yamamoto M, Yoshida K, Ohno F. Increase of plasma proapolipoprotein A-I in patients with liver cirrhosis and its relationship to circulating high-density lipoproteins 2 and 3. Clin Chem 1993;39:60-5.
37. Ghiselli G, Gotto AM Jr, Tanenbaum S, Sherrill BC. Proapolipoprotein A-I conversion kinetics in vivo in human and in rat. Proc Natl Acad Sci U S A 1985;82:874-8.
38. De Vries HE, Breedveld B, Kuiper J, De Boer AG, Van Berkel TJ, Breimer DD. High-density lipoprotein and cerebral endothelial cells in vitro: interactions and transport. Biochem Pharmacol 1995;50:271-3.
39. Koch S, Donarski N, Goetze K et al. Characterization of four lipoprotein classes in human cerebrospinal fluid. J Lipid Res 2001;42:1143-51.
40. Paula-Lima AC, Tricerri MA, Brito-Moreira J et al. Human apolipoprotein A-I binds amyloid-beta and prevents Abeta-induced neurotoxicity. Int J Biochem Cell Biol 2009;41:1361-70.
41. Davidsson P, Westman-Brinkmalm A, Nilsson CL et al. Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients. Neuroreport 2002;13:611-5.
42. Dietschy JM, Turley SD. Cholesterol metabolism in the brain. Curr Opin Lipidol 2001;12:105-12.
43. Koldamova RP, Lefterov IM, Lefterova MI, Lazo JS. Apolipoprotein A-I directly interacts with amyloid precursor protein and inhibits A beta aggregation and toxicity. Biochemistry 2001;40:3553-60.
44. Song H, Saito K, Seishima M, Noma A, Urakami K, Nakashima K. Cerebrospinal fluid apo E and apo A-I concentrations in early- and late-onset Alzheimer's disease. Neurosci Lett 1997;231:175-8.
45. Puchades M, Hansson SF, Nilsson CL, Andreasen N, Blennow K, Davidsson P. Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimer's disease. Brain Res Mol Brain Res 2003;118:140-6.
46. Castano EM, Roher AE, Esh CL, Kokjohn TA, Beach T. Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects. Neurol Res 2006;28:155-63.